Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03770260 · FLOW

Participant flow

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment · Source last updated 2025-06-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Pevonedistat 20 mg/meter squared given by infusion and ixazomib 4 mg taken by mouth on days 1, 8 and 15 of every 28-day cycle.
    id
    FG000
    title
    Dose Level 1
  2. description
    Pevonedistat 40 mg/meter squared given by infusion and ixazomib 4 mg taken by mouth on days 1, 8 and 15 of every 28-day cycle.
    id
    FG001
    title
    Dose Level 2
  3. description
    Pevonedistat 60 mg/meter squared given by infusion and ixazomib 4 mg taken by mouth on days 1, 8 and 15 of every 28-day cycle.
    id
    FG002
    title
    Dose Level 3
  4. description
    Pevonedistat at the maximum tolerated dose determined in the dose levels given by infusion and ixazomib 4 mg taken by mouth on days 1, 8 and 15 of every 28-day cycle.
    id
    FG003
    title
    Dose Expansion
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Disease progression
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        4
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        3
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Pevonedistat 20 mg/meter squared given by infusion and ixazomib 4 mg taken by mouth on days 1, 8 and 15 of every 28-day cycle.
    id
    FG000
    title
    Dose Level 1
  2. description
    Pevonedistat 40 mg/meter squared given by infusion and ixazomib 4 mg taken by mouth on days 1, 8 and 15 of every 28-day cycle.
    id
    FG001
    title
    Dose Level 2
  3. description
    Pevonedistat 60 mg/meter squared given by infusion and ixazomib 4 mg taken by mouth on days 1, 8 and 15 of every 28-day cycle.
    id
    FG002
    title
    Dose Level 3
  4. description
    Pevonedistat at the maximum tolerated dose determined in the dose levels given by infusion and ixazomib 4 mg taken by mouth on days 1, 8 and 15 of every 28-day cycle.
    id
    FG003
    title
    Dose Expansion
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Disease progression
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        4
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        3
      2. group Id
        FG001
        num Subjects
        3
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice